Literature DB >> 11454692

Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.

S K Diah1, P K Smitherman, J Aldridge, E L Volk, E Schneider, A J Townsend, C S Morrow.   

Abstract

We examined the role of multidrug resistance protein (MRP) 1 (ABCC1) in the emergence of mitoxantrone (MX) cross-resistance in a MCF7 breast cancer cell line selected for resistance to etoposide. The resistant cell line, MCF7/VP, expresses high levels of MRP1, whereas the parental cell line, MCF7/WT, does not. MCF7/VP cells are 6-10-fold cross-resistant to MX when compared with MCF7/WT cells. Drug transport studies in intact MCF7/VP cells revealed that MX resistance is associated with reduced MX accumulation due to enhanced MX efflux. MX efflux is ATP dependent and inhibited by sulfinpyrazone and cyclosporin A. Inhibition of MX efflux with these agents sensitizes cells to MX cytotoxicity and partially reverses MX resistance in MCF7/VP cells. Whereas resistance is partially attributable to increased MX efflux in MRP1-expressing MCF7/VP cells, we found no evidence for glutathione or other conjugates of MX in these cells. Moreover, glutathione depletion with buthionine sulfoximine had no effect on MX transport or sensitivity in MCF7/VP cells. MRP1 substrates are generally amphiphilic anions such as glutathione conjugates or require the presence of physiological levels of glutathione for MRP1-mediated transport. Therefore we conclude that MRP1 overexpression is unlikely to be responsible for increased MX efflux and resistance in MCF7/VP cells. In considering the potential involvement of other MRP family isoforms, a 3-fold increase in the expression of MRP5 was observed in MCF7/VP cells. However, stable expression of a transduced MRP5 expression vector in MCF7/WT cells failed to confer MX resistance. Because other transporters known to be associated with MX resistance, including P-glycoprotein and BCRP/MXR (ABCG2), are not expressed in MCF7/VP cells, we conclude that increased MX efflux and resistance in MCF7/VP cells is attributable to a novel transport mechanism or that MX represents a novel class of cationic, glutathione-independent MRP1 substrates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454692

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Emerging strategies for the identification and targeting of cancer stem cells.

Authors:  Jun Dou; Ning Gu
Journal:  Tumour Biol       Date:  2010-03-25

Review 2.  Transporters in the intestine limiting drug and toxin absorption.

Authors:  R P J Oude Elferink; R de Waart
Journal:  J Physiol Biochem       Date:  2007-03       Impact factor: 4.158

3.  Priming cancer cells for drug resistance: role of the fibroblast niche.

Authors:  Wei Bin Fang; Min Yao; Nikki Cheng
Journal:  Front Biol (Beijing)       Date:  2014-02-01

4.  Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro.

Authors:  Guohua An; Marilyn E Morris
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

5.  Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

Authors:  David Becton; Gary V Dahl; Yaddanapudi Ravindranath; Myron N Chang; Fred G Behm; Susana C Raimondi; David R Head; Kimo C Stine; Norman J Lacayo; Branimir Ivan Sikic; Robert J Arceci; Howard Weinstein
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

6.  Human multidrug resistance associated protein 4 confers resistance to camptothecins.

Authors:  Quan Tian; Jing Zhang; Theresa May Chin Tan; Eli Chan; Wei Duan; Sui Yung Chan; Urs Alex Boelsterli; Paul Chi-Lui Ho; Hongyuan Yang; Jin-Song Bian; Min Huang; Yi-Zhun Zhu; Weiping Xiong; Xiaotian Li; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

7.  Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression.

Authors:  Ketki M Hatle; Wendy Neveu; Oliver Dienz; Stacia Rymarchyk; Ramiro Barrantes; Sarah Hale; Nicholas Farley; Karen M Lounsbury; Jeffrey P Bond; Douglas Taatjes; Mercedes Rincón
Journal:  Mol Cell Biol       Date:  2007-02-05       Impact factor: 4.272

8.  Reduction of 99mTc-sestamibi and 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function.

Authors:  Seigo Kinuya; Xiao-Feng Li; Kunihiko Yokoyama; Hirofumi Mori; Kazuhiro Shiba; Naoto Watanabe; Noriyuki Shuke; Hisashi Bunko; Takatoshi Michigishi; Norihisa Tonami
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-31       Impact factor: 9.236

9.  Resistance to thapsigargin-induced intracellular calcium mobilization in a multidrug resistant tumour cell line.

Authors:  Karen Wagner-Souza; Juliana Echevarria-Lima; Louise A P Rodrigues; Marcelo Reis; Vivian M Rumjanek
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

10.  Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.

Authors:  R Boonstra; H Timmer-Bosscha; J van Echten-Arends; D M van der Kolk; A van den Berg; B de Jong; K D Tew; S Poppema; E G E de Vries
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.